Wordt geladen...
SS-1 Therapeutic challenges for glioblastoma: Temozolomide and its issues?
Glioblastoma (GBM), the most malignant form (WHO grade IV) of gliomas, remains incurable despite recent advances in medical technologies and molecular knowledge, with 5-year survival rate being just beyond 10%, thus undoubtedly leaving unmet needs to develop effective therapeutics to improve outcome...
Bewaard in:
| Gepubliceerd in: | Neurooncol Adv |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Oxford University Press
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7699118/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa143.002 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|